ERBB2 and ovarian carcinoma: Though the clinical value of single-agent trastuzumab seems to be limited by the low response rate in HER2 overexpressing ovarian cancer patients, researchers demonstrated that HER receptor expression by cancer cells may not give an accurate prediction on the responsiveness to HER-targeted therapeutic agents [113,114].